A Pilot Study of Brentuximab Vedotin in the Prevention of Graft-Versus-Host Disease (GVHD) After Mismatched Unrelated Allogeneic Stem Cell Transplantation
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary) ; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions
- 12 Apr 2019 Status changed from active, no longer recruiting to completed.
- 02 Mar 2017 Planned End Date changed from 1 Jan 2017 to 31 Jan 2020.
- 19 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Jan 2017.